The diagnostic PSMA-targeting PET radiopharmaceutical 18F-flotufolastat (18F-rhPSMA-7.3) is currently approved for clinical use in the USA in patients with recurrent prostate cancer, following findings from the phase 3 SPOTLIGHT study (NCT04186845) [12]. Here, FOLH1 is linked to prostate cancer.